Page 131 - 《中国药房》2024年15期

（10）：e1633235. [25] YUAN B，MA J C，WANG J，et al. The effect of metfor‐
[14] WANG S H，LIN Y S，XIONG X，et al. Low-dose metfor‐ min usage on survival outcomes for hepatocellular carci‐
min reprograms the tumor immune microenvironment in noma patients with type 2 diabetes mellitus after curative
human esophageal cancer：results of a phase Ⅱ clinical therapy[J]. Front Endocrinol，2022，13：1060768.
trial[J]. Clin Cancer Res，2020，26（18）：4921-4932. [26] SUN R J，ZHAI R R，MA C L，et al. Combination of aloin
[15] LU Y，XIN D，GUAN L L，et al. Metformin downregu‐ and metformin enhances the antitumor effect by inhibiting
lates PD-L1 expression in esophageal squamous cell the growth and invasion and inducing apoptosis and au‐
carcinoma by inhibiting IL-6 signaling pathway[J]. Front tophagy in hepatocellular carcinoma through PI3K/AKT/
Oncol，2021，11：762523. mTOR pathway[J]. Cancer Med，2020，9（3）：1141-1151.
[16] PENG J W，JING X B，WU J L，et al. Metformin’s effects [27] RICHARDS K A，LIOU J I，CRYNS V L，et al. Metfor‐
on apoptosis of esophageal carcinoma cells and normal min use is associated with improved survival for patients
esophageal epithelial cells：an in vitro comparative study with advanced prostate cancer on androgen deprivation
[J]. Biomed Res Int，2020，2020：1068671. therapy[J]. J Urol，2018，200（6）：1256-1263.
[17] HONG J，MAACHA S，PIDKOVKA N，et al. AXL pro‐ [28] FREEDMAN L S，AGAY N，FARMER R，et al. Metfor‐
motes metformin-induced apoptosis through mediation of min treatment among men with diabetes and the risk of
autophagy by activating ROS-AMPK-ULK1 signaling in prostate cancer：a population-based historical cohort study
human esophageal adenocarcinoma[J]. Front Oncol，2022， [J]. Am J Epidemiol，2022，191（4）：626-635.
12：903874. [29] YE J H，CAI S H，FENG Y F，et al. Metformin escape in
[18] BULLMAN S，PEDAMALLU C S，SICINSKA E，et al. prostate cancer by activating the PTGR1 transcriptional
Analysis of Fusobacterium persistence and antibiotic re‐ program through a novel super-enhancer[J]. Signal Trans‐
sponse in colorectal cancer[J]. Science，2017，358（6369）： duct Target Ther，2023，8（1）：303.
1443-1448. [30] BROWN J R，CHAN D K，SHANK J J，et al. Phase Ⅱ
[19] HONG X L，YU T C，HUANG X W，et al. Metformin clinical trial of metformin as a cancer stem cell-targeting
abrogates Fusobacterium nucleatum-induced chemoresis‐ agent in ovarian cancer[J]. JCI Insight，2020，5（11）：
tance in colorectal cancer by inhibiting miR-361-5p/sonic e133247.
Hedgehog signaling-regulated stemness[J]. Br J Cancer， [31] DANG J H，JIN Z J，LIU X J，et al. Metformin in combi‐
2023，128（2）：363-374. nation with cisplatin inhibits cell viability and induces
[20] NG C W，JIANG A A，TOH E M S，et al. Metformin and apoptosis of human ovarian cancer cells by inactivating
colorectal cancer：a systematic review，meta-analysis and ERK1/2[J]. Oncol Lett，2017，14（6）：7557-7564.
meta-regression[J]. Int J Colorectal Dis，2020，35（8）： [32] SINGH S K，APATA T，SINGH S，et al. Clinical implica‐
1501-1512. tion of metformin in relation to diabetes mellitus and
[21] HUANG X W，SUN T T，WANG J L，et al. Metformin re‐ ovarian cancer[J]. Biomedicines，2021，9（8）：1020.
programs tryptophan metabolism to stimulate CD8 T-cell [33] TANG G H，SATKUNAM M，POND G R，et al. Asso-
+
function in colorectal cancer[J]. Cancer Res，2023，83 ciation of metformin with breast cancer incidence and
（14）：2358-2371. mortality in patients with type Ⅱ diabetes：a GRADE-
[22] SHI Y Q，ZHOU X C，DU P，et al. Relationships are assessed systematic review and meta-analysis[J]. Cancer
between metformin use and survival in pancreatic cancer Epidemiol Biomarkers Prev，2018，27（6）：627-635.
patients concurrent with diabetes：a systematic review and [34] WANG Q D，MA X F，LONG J P，et al. Metformin and
meta-analysis[J]. Medicine，2020，99（37）：e21687. survival of women with breast cancer：a meta-analysis of
[23] SCARTON L，JO A，XIE Z G，et al. Examining the rela‐ randomized controlled trials[J]. J Clin Pharm Ther，2022，
tionship between metformin dose and cancer survival：a 47（3）：263-269.
SEER-medicare analysis[J]. PLoS One，2022，17（10）： [35] RAHMANI J，MANZARI N，THOMPSON J，et al. The
e0275681. effect of metformin on biomarkers associated with breast
[24] REN D Y，QIN G D，ZHAO J Y，et al. Metformin ac- cancer outcomes：a systematic review，meta-analysis，and
tivates the STING/IRF3/IFN- β pathway by inhibiting dose-response of randomized clinical trials[J]. Clin Transl
AKT phosphorylation in pancreatic cancer[J]. Am J Oncol，2020，22（1）：37-49.
Cancer Res，2020，10（9）：2851-2864. [36] SERAGELDIN M A，KASSEM A B，EL-KERM Y，et al.

中国药房 2024年第35卷第15期 China Pharmacy 2024 Vol. 35 No. 15 · 1921 ·